Target intelligence / Profile preview

Gut microbiota ecosystem and Clostridioides difficile ecological niche

Molecular classification
Other
01

Overview

The gut microbiota ecosystem is a complex consortium of microorganisms that provides a protective barrier against pathogens through a phenomenon known as colonization resistance (Britton & Young, 2014, Gastroenterology). Clostridioides difficile exploits an ecological niche that becomes available when this community is disrupted, typically by antibiotic treatment that reduces microbial diversity and alters the metabolic environment (Seekatz & Young, 2014, J. Clin. Invest.). In a healthy ecosystem, commensal bacteria compete with C. difficile for limited nutrients and produce metabolites, such as secondary bile acids, that directly inhibit its vegetative growth (Buffie et al., 2015, Nature). Therapeutic interventions like fecal microbiota transplantation (FMT) or live biotherapeutic products (e.g., Vowst, Rebyota) aim to re-populate this niche with diverse commensals to restore these inhibitory mechanisms (FDA, 2023, Vowst Prescribing Information). This ecological approach shifts the treatment paradigm from direct pathogen eradication to the restoration of a resilient microbial community capable of self-regulating against infection.

Other names
Gut microbiomeIntestinal microbiotaCommensal bacterial communityC. difficile nicheIntestinal flora
02

Mechanism of action

Restoration of colonization resistance through competitive exclusion for nutrients and the enzymatic conversion of primary bile acids to secondary bile acids, which inhibits C. difficile vegetative growth (Buffie et al., 2015, Nature; Britton & Young, 2014, Gastroenterology).

03

Biological functions

Colonization resistanceBile acid metabolismNutrient competitionImmune system modulationMetabolic homeostasis
04

Disease associations

Clostridioides difficile infectionDysbiosisAntibiotic-associated diarrheaInflammatory bowel disease
05

Safety considerations

Transmission of donor-derived infectious agentsGastrointestinal adverse events (bloating, abdominal pain)Risk of bacteremia in severely immunocompromised patientsLong-term impact on host immune and metabolic health
06

Interacting drugs

Fecal microbiota spores, live-brpk (Vowst)

4 more in the full profile.

07

Biomarkers

Microbial diversity (Alpha diversity/Shannon index)Secondary bile acid concentrationPresence of Clostridium scindensBacteroidetes-to-Firmicutes ratioC. difficile toxin A/B

Beyond the preview

Go deeper on Gut microbiota ecosystem and Clostridioides difficile ecological niche.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbiota ecosystem and Clostridioides difficile ecological niche.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call